Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A412006-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $99.90 | |
| A412006-1mg | 1mg | In stock | $454.90 | |
| A412006-5mg | 5mg | In stock | $1,894.90 | |
| A412006-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,410.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Avelumab (anti-PD-L1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to B7-H1 / PD-L1 / CD274, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Recombinant Avelumab Antibody; Avelumab; Anti-Human PD-L1, Human Antibody; Anti-PD-L1; MSB0010718C; Bavencio; B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibo |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | B7-H1 / PD-L1 / CD274 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | OTHER |
| Mechanism of action | OTHER of Programmed cell death 1 ligand 1 other |
| Product Description | Avelumab is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | lambda |
| SDS-PAGE | 28.7 kDa (Light Chain) & 50.1 kDa (Heavy Chain), under reducing conditions; 182.4 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1537032-82-8 |
Avelumab (anti-PD-L1) (A412006) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood lymphocytes labelling PD-L1 with Avelumab (anti-PD-L1) (A412006) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Avelumab (anti-PD-L1) (A412006) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood lymphocytes labelling PD-L1 (red) with Avelumab (anti-PD-L1) (A412006) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Avelumab (anti-PD-L1) (A412006) - SEC
The purity of Avelumab (anti-PD-L1) (A412006) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| IMGT/mAb-DB | 512 |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0404943 | Certificate of Analysis | Apr 26, 2024 | A412006 |
| ZJ23F1101612 | Certificate of Analysis | Nov 08, 2023 | A412006 |
| ZJ23F1101613 | Certificate of Analysis | Nov 08, 2023 | A412006 |
| 1. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy.. Nat Rev Cancer, 12 (4): (252-64). [PMID:22437870] |
| 2. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy.. Cancer Cell, 27 (4): (450-61). [PMID:25858804] |
